Janux Therapeutics, Inc. (NASDAQ:JANX) Position Raised by Franklin Resources Inc.

Franklin Resources Inc. lifted its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 64.5% in the 3rd quarter, Holdings Channel reports. The fund owned 18,983 shares of the company’s stock after buying an additional 7,442 shares during the period. Franklin Resources Inc.’s holdings in Janux Therapeutics were worth $937,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of JANX. Amalgamated Bank grew its position in Janux Therapeutics by 61.1% in the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after purchasing an additional 368 shares during the last quarter. Plato Investment Management Ltd acquired a new position in shares of Janux Therapeutics during the second quarter worth approximately $42,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Janux Therapeutics by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after buying an additional 339 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Janux Therapeutics in the 2nd quarter valued at approximately $151,000. Finally, AQR Capital Management LLC bought a new stake in Janux Therapeutics during the 2nd quarter valued at $215,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Insiders Place Their Bets

In other Janux Therapeutics news, Director Ra Capital Management, L.P. bought 1,200,000 shares of the firm’s stock in a transaction dated Friday, October 18th. The stock was acquired at an average price of $44.75 per share, with a total value of $53,700,000.00. Following the completion of the transaction, the director now directly owns 9,317,246 shares in the company, valued at approximately $416,946,758.50. This represents a 14.78 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Ventures Xi L.P. Avalon sold 958 shares of Janux Therapeutics stock in a transaction on Monday, September 30th. The shares were sold at an average price of $46.24, for a total value of $44,297.92. Following the transaction, the insider now owns 6,887 shares in the company, valued at $318,454.88. This represents a 12.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 92,801 shares of company stock worth $5,174,735 over the last ninety days. 29.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a research note on Tuesday, December 3rd. Leerink Partners increased their target price on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research report on Tuesday, December 3rd. HC Wainwright boosted their price target on shares of Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. BTIG Research increased their price objective on shares of Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $200.00 target price on shares of Janux Therapeutics in a report on Wednesday, December 11th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $89.90.

Janux Therapeutics Stock Down 1.9 %

JANX opened at $54.10 on Friday. The firm has a market cap of $2.84 billion, a PE ratio of -46.24 and a beta of 3.29. The business has a fifty day simple moving average of $54.43 and a 200-day simple moving average of $47.46. Janux Therapeutics, Inc. has a fifty-two week low of $7.79 and a fifty-two week high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The company had revenue of $0.44 million during the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The company’s revenue for the quarter was down 82.6% on a year-over-year basis. On average, equities research analysts anticipate that Janux Therapeutics, Inc. will post -1.35 EPS for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.